Real-World Adherence to OnabotulinumtoxinA Treatment for Spasticity: Insights from the ASPIRE Study
Francisco, Gerard E
Bandari, Daniel S
Wittenberg, George F
JournalArchives of Physical Medicine and Rehabilitation
MetadataShow full item record
AbstractObjective: To identify baseline characteristics and treatment-related variables that impact adherence to onabotulinumtoxinA treatment from the Adult Spasticity International Registry (ASPIRE) study. Design: Prospective, observational registry (NCT01930786). Setting: International clinical sites. Participants: Adults with spasticity. Interventions: OnabotulinumtoxinA at clinician's discretion. Main outcome measure(s): Clinically meaningful thresholds used for treatment adherent (≥3 treatment sessions during 2-year study) and non-adherent (≤2 sessions). Data analyzed using logistic regression and presented as odds ratios (OR) with 95% confidence intervals (CI). Treatment-related variables assessed at sessions 1 and 2 only. Results: Of the total population (N=730), 523 patients (71.6%) were treatment adherent with 5.3 (1.6; mean [SD]) sessions; 207 (28.4%) non-adherent with 1.5 (0.5). In the final model (n=626/730), 522 patients (83.4%) were treatment adherent, 104 (16.6%) were non-adherent. Baseline characteristics associated with adherence: treated in Europe (OR:1.84, CI:1.06-3.21; P=0.030) and use of orthotics (OR:1.88, CI:1.15-3.08; P=0.012). Baseline characteristics associated with non-adherence: history of diplopia (OR:0.28, CI:0.09-0.89; P=0.031) and use of assistive devices (OR:0.51, CI:0.29-0.90; P=0.021). Treatment-related variables associated with non-adherence: treatment interval ≥15 weeks (OR:0.43, CI:0.26-0.72; P=0.001) and clinician dissatisfaction with onabotulinumtoxinA to manage pain (OR:0.18, CI:0.05-0.69; P=0.012). Of the stroke population (N=411), 288 patients (70.1%) were treatment adherent with 5.3 (1.6; mean [SD]) sessions; 123 (29.9%) non-adherent with 1.5 (0.5). In the final stroke model (n=346/411), 288 patients (83.2%) were treatment adherent, 58 (16.8%) were non-adherent. Baseline characteristics associated with adherence: treated in Europe (OR:2.99, CI:1.39-6.44; P=0.005) and use of orthotics (OR:3.18, CI:1.57-6.45; P=0.001). Treatment-related variables associated with non-adherence: treatment interval ≥15 weeks (OR:0.42, CI:0.21-0.83; P=0.013) and moderate/severe disability on upper limb DAS pain subscale (OR:0.40, CI:0.19-0.83; P=0.015). Conclusions: These ASPIRE analyses demonstrate real-world patient and clinical variables that impact adherence to onabotulinumtoxinA and provide insights to help optimize management strategies to improve patient care.
Rights/TermsCopyright © 2021. Published by Elsevier Inc.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16200
- Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study.
- Authors: Francisco GE, Jost WH, Bavikatte G, Bandari DS, Tang SFT, Munin MC, Largent J, Adams AM, Zuzek A, Esquenazi A
- Issue date: 2020 Nov
- High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study.
- Authors: Francisco GE, Bandari DS, Bavikatte G, Jost WH, McCusker E, Largent J, Zuzek A, Esquenazi A
- Issue date: 2020 Sep
- Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity.
- Authors: Esquenazi A, Bavikatte G, Bandari DS, Jost WH, Munin MC, Tang SFT, Largent J, Adams AM, Zuzek A, Francisco GE
- Issue date: 2021 Oct
- Suicidal Ideation
- Authors: Harmer B, Lee S, Duong TvH, Saadabadi A
- Issue date: 2021 Jan
- BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
- Authors: Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L, BoTULS investigators.
- Issue date: 2010 May